Use of Enoxaparin in Patients Undergoing Percutaneous Coronary Intervention

Critical Pathways in Cardiology

Volumn 2, Issue 1, 2003, Pages 1-6

  Kadakia, Rajan A ^a   Ferguson, James J ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ANTICOAGULANT THERAPY; BLEEDING; CATHETERIZATION; CLINICAL TRIAL; CORONARY STENT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0345686498     PISSN: 1535282X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HPC.0000053683.27900.84     Document Type: Review

References (18)

1. Weitz J. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
2. Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994;71:300-4.
3. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999;100:1593-601.
4. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
5. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1586-9.
6. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-74.
7. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Inv Cardiol 2001;14:272-8.
8. The EPISTENT Investigators. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: The EPISTENT investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
9. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Eng J Med 1997;336: 1689-98.
10. Bhatt DL, Lincoff AM. Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: The results of the CRUISE trial. Circulation 2001;104:384-5.
11. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
12. Martin JL, Fry ETA, Serano A, et al. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes: The PEPCI study. Eur Heart J 2001;22:14.
13. Ferguson JJ, Antman EM, Bates ER, et al. The use of enoxaparin and IIb/IIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study [abstract]. J Am Coll Cardiol 2001;37:365A.
14. Goodman S. LBCT: Integrelin and Enoxaparin in Acute Coronary Syndrome Treatment (INTERACT). Presented at the American College of Cardiology Annual Scientific Sessions. March 17-20, 2002; Atlanta, Georgia.
15. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-9.
16. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002;360(9335):743-51.
17. Dubois C, Belmans A, Armstrong P, et al. Outcome of elective percutaneous interventions in ASSENT-3 [abstract P1797]. Eur Heart J ESC 2002.
18. The SYNERGY Executive Committee. The SYNERGY trial: study design and rationale. Am Heart J 2002;143: 952-60.